Moreover, our finding that chemical inhibition of mTOR promotes strong in vivo proliferation of KRAS-G12D B-ALL cells clearly differentiates the impacts of hyperactivated AKT/mTOR signaling in RAS mutant hematological malignancies from previous impacts reported for RAS mutant solid carcinomas. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.